Innate Pharma (IPHA) announced that in an abstract published on May 14 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi (SNY), it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has FDA Fast Track Designation, as communicated before in June 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue